secwatch.observer — SEC 8-K summary
======================================

Issuer:     Equillium, Inc. (EQ)
CIK:        0001746466
Form:       8-K
Filed at:   2024-10-31T23:59:59+00:00
Accession:  0001193125-24-248138
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Equillium announces Ono option lapse; pauses EQUATOR enrollment to review acceleration; cash runway into Q4 2025
--------------------------------------------------------------------------------

- Ono's option to acquire itolizumab (EQ001) lapsed; Equillium retains all commercial rights to itolizumab.
- EQUATOR Phase 3 study enrollment paused; company plans to accelerate topline data to Q1 2025 with ~150 patients.
- Over 150 patients enrolled to date; orphan drug and fast track designations for first-line acute GVHD remain.
- Biocon SA completed Phase 2 study of itolizumab in ulcerative colitis; topline data expected Q1 2025.
- Company pauses EQ101 and EQ302 activities; cash runway expected into Q4 2025 with accelerated EQUATOR.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746466/000119312524248138/0001193125-24-248138-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746466/000119312524248138/d787967d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-248138

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer